Chan Heng Fai Ambrose - 10 Dec 2024 Form 4 Insider Report for DSS, INC. (DSS)

Role: Director, 10%+ Owner
Signature: /s/ Heng Fai Ambrose Chan
Issuer symbol: DSS
Transactions as of: 10 Dec 2024
Net transactions value: +$1,000,000
Form type: 4
Filing time: 12 Dec 2024, 21:49:45 UTC
Previous filing: 26 Nov 2024
Next filing: 26 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DSS	Common Stock	Purchase	$800,000	+820,597	+26%	$0.9749	3,961,211	10 Dec 2024	See footnote	F1, F2
transaction	DSS	Common Stock	Purchase	$200,000	+205,149	+21%	$0.9749	1,184,475	10 Dec 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 10, 2024, Alset Inc. entered into a stock purchase agreement with DSS, Inc. (the "Issuer"), pursuant to which Alset Inc. agreed to purchase 820,597 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Alset Inc. and its various subsidiaries are collectively the largest shareholder of DSS. Further, on December 10, 2024, Mr. Chan directly entered into a stock purchase agreement with the Issuer, pursuant to which he agreed to purchase 205,149 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Mr. Chan is the Executive Chairman of DSS.
F2	The beneficial ownership of Mr. Chan includes a total of 5,148,664 shares of common stock, consisting of (a) 2,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

Content

On December 10, 2024, Alset Inc. entered into a stock purchase agreement with DSS, Inc. (the "Issuer"), pursuant to which Alset Inc. agreed to purchase 820,597 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Alset Inc. and its various subsidiaries are collectively the largest shareholder of DSS. Further, on December 10, 2024, Mr. Chan directly entered into a stock purchase agreement with the Issuer, pursuant to which he agreed to purchase 205,149 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Mr. Chan is the Executive Chairman of DSS.

The beneficial ownership of Mr. Chan includes a total of 5,148,664 shares of common stock, consisting of (a) 2,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).